Latest Anxiety Disorder Treatment Companies Update
February 2023: Biogen Inc. and Sage Therapeutics, Inc. have jointly declared that their New Drug Application (NDA) for zuranolone, a treatment for major depressive disorder (MDD) and postpartum depression (PPD), has been approved by the U.S. Food and Drug Administration (FDA). An investigational substance, Zuranolone, is undergoing clinical evaluation as a once-daily, rapid-acting, 14-day oral treatment for adults diagnosed with MDD and PPD. Priority review has been allotted to the application, and August 5, 2023 has been designated as the Prescription Drug User Fee Act (PDUFA) action date by the FDA. The NDA for zuranolone comprises information derived from the LANDSCAPE and NEST clinical development programs, in addition to a Phase 2 study conducted by Shionogi in Japan involving adults diagnosed with MDD.
November 2022: The Institute of Mental Health and the Singaporean technology startup Neeuro have jointly introduced a home-based attention training program.  Cogo is a digital therapeutic program designed to address inattentiveness in children ages 6 to 12 by pairing a 24-session guided game with the Neeuro SenzeBand 2 EEG headgear. It was created utilizing the Brain-Computer Interface technology of Neeuro. The objective of the mobile game, as stated in a press release, is to guide a character through a labyrinth. In contrast to most games, in which the user interacts with the characters via a touchscreen or gamepad, Cogo exclusively utilizes brainwaves to control the characters. Its associated headgear monitors the brainwaves of users via seven EEG sensors with four distinct data channels. Subsequently, these are captured and interpreted by AI algorithms, which utilize the real-time Bluetooth transmissions to generate challenges within the game.
List of Anxiety Disorder Treatment Key companies in the market
- Bristol-Myers Squibb Company (US)
- Lundbeck A/S (Denmark)
- Johnson and Johnson (US)
- GlaxoSmithKline PLC (UK)
- Pfizer
- Merck & Co.
- Sanofi-Aventis (France)
- AstraZeneca PLC (UK)
- Forest Laboratories
- Eli Lily and Company (US)